MedTrace Logo

Microbial and Pharmacological Assessment of Chlorhexidine

NCT03290105 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2017-09-25

No results posted yet for this study

Summary

Ventilator-associated pneumonia (VAP) is the most frequent life-threatening nosocomial infection in the ICU. Oropharyngeal colonization with bacterial pathogens is the first step toward lung infection. Oral hygiene with Chlorhexidine mouth wash (CMW) is among the most widespread preventive measure to prevent VAP. Precise microbial documentation of CMW efficacy on oropharyngeal colonization is lacking. Investigators wish to determine CMW antimicrobial efficacy in ICU ventilated patients and to measure chlorhexidine residual concentration in patients' saliva at the same time-points after CMW.

Conditions

  • Oropharynx Abnormality
  • Pneumonia, Ventilator-Associated
  • Chlorhexidine
  • Bacterium; Agent
  • Infection, Bacterial

Sponsors & Collaborators

  • Hôpital Louis Mourier

    lead OTHER

Principal Investigators

  • Jean-Damien Ricard, MD, PhD · Assistance Publique - Hôpitaux de Paris

  • Béatrice La Combe, MD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-27
Primary Completion
2014-03-31
Completion
2016-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03290105 on ClinicalTrials.gov